<DOC>
	<DOCNO>NCT01270724</DOCNO>
	<brief_summary>This study look see well patient relapse recurrent intracranial germ cell tumor respond new combination chemotherapy ( induction ) Gemcitabine , Paclitaxel Oxaliplatin ( GemPOx ) follow consolidation chemotherapy autologous stem cell rescue .</brief_summary>
	<brief_title>Gemcitabine , Paclitaxel Oxaliplatin ( GemPOx )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>ICGCT include pure germinoma MMGCT . Patients histologically proven germinoma MMGCT , include endodermal sinus tumor ( yolk sac tumor ) , embryonal carcinoma , choriocarcinoma mixed germ cell tumor eligible study . Patients mature/immature teratoma tumor marker elevation eligible study . Patient ONLY mature and/or immature teratoma ineligible absence tumor marker elevation . Patients ICGCTs newly diagnose exclude study . Patients diagnosis mature immature teratoma absence tumor marker elevation exclude study . Patients pregnant breastfeed exclude study . Patients receive previously high dose chemotherapy regimen autologous transplant exclude study . Patients receive gemcitabine , oxaliplatin and/or paclitaxel exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>